Overview

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Status:
RECRUITING
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Phase:
PHASE1
Details
Lead Sponsor:
Corcept Therapeutics
Collaborator:
University of Missouri-Columbia